arthritis, inflammatory eye diseases, inflammatory bowel disease, chronic pancreatitis and cancers in several independent phase I and phase II clinical trials
. [11] [12] [13] . As demonstrated in clinical studies, curcumin possesses poor pharmacokinetic profiles, such as low bioavailability and rapid metabolism. In a recent phase II trial, the curcumin level in plasma reached only up to 22-41 ng/ml even after administering a daily oral dose of 8.0 g/day for 4 weeks [14] .
Although curcumin can be safely used with an oral dose as high as 12 g/day, its clinical applications have been significantly limited by its instability and poor metabolic properties
It has been suggested that ␤-diketone moiety may be responsible for such rapid degradation and poor bioavailability of curcumin. Recent reports have demonstrated the ␤-diketone moiety in curcumin is a specific substrate for liver aldo-keto reductases. Presence of ␤-diketone may be one of main factors contributing to the rapid metabolism of curcumin in vivo [15, 16] . In our previous publication, we have demonstrated design and synthesis of a series of curcumin mono-carbonyl analogues without the ␤-diketone moiety (showed in Fig. 1 ) [17, 18] . We have also showed that these analogues, without ␤-diketone, exhibited enhanced stability in vitro and improved pharmacokinetic profiles in vivo [19] . We evaluated a total of 87 analogues for anti-inflammatory properties using LPS-stimulated mouse J774.1A macrophages, 43 of which were reported previously [18] . Fig. 2 ). Using the synthetic routes we previously reported [17] Fig. 4) the genesis and development of inflammation [20, 21] . Hence, the effects of compounds A01, A13 and B18 were further evaluated with respect to such mRNA expression. The cells were treated with compounds and LPS and total RNA was extracted. Specific mRNAs were detected by real-time RT-PCR (shown in Fig. 5 [9, [20] [21] [22] Fig. 5B , LPSinduced mRNA expressions of three inflammatory enzymes were significantly reduced by A01, A13, B18 and curcumin at 10 M [25, 26] . In this section, we investigated the effects of NF-B p65 mRNA expression by curcumin and active analogues in order to know about their abilities in the level of transcription factor. As shown in Fig. 6 [27] [28] [29] [30] [31] . Considering that the presence of ␤-diketone moiety may result in the instability and poor metabolic properties of curcumin, we have previously designed a series of mono-carbonyl analogues of curcumin with enhanced stability in vitro and improved pharmacokinetic profiles in vivo [17] [18] [19] . In the present study, 44 mono-carbonyl analogues were evaluated for the inhibitory activities against LPS-induced TNF-␣ and IL-6 release in macrophages in an attempt to identify compounds with potent biological activities, which can be targeted for development as pharmaceutical agents.
RNA isolation and real-time quantitative PCR

Results
Synthesis of curcumin analogues
Three series of dienones, 1,5-diaryl-1,4-pentadiene-3-ones(B), together with cyclopentanone(A) and cyclohexanone(C) analogues, were designed by displacing ␤-diketone moiety with a single carbonyl group (shown in
Inhibition of the LPS-induced TNF-␣ and IL-6 release by curcumin analogues
(COX-2), prostaglandin E synthase (PGES) and inducible NO synthase (iNOS) have been demonstrated as inflammatory enzymes that are altered in inflammation and in various disease states in humans. They have also been reported to be responsive to the LPS stimulation
. To determine whether curcumin and its analogs also have any inhibitory effects on the expression of inflammatory enzymes in macrophages, total mRNA was extracted and mRNA of COX-2, PGES and iNOS was, respectively, analyzed by real-time RT-PCR after cells were treated with compounds and LPS for 24 hrs. As shown in
concentration. Although the inhibitory effects of analogues were not as pronounced as that of curcumin in COX-2 and iNOS groups, the majority of them reduced LPS-induced expressions of mRNAs below the level of the control group. In PGES group, A13 and B18 exhibited slightly stronger inhibitory effects than curcumin.
Compounds A01, A13 and B18 inhibit the NF-B p65 mRNA expression
NF-B is an LPS-inducible transcription factor that plays a central role in the mammalian innate immune response and inflammation. The activation of NF-B is exerted through the regulation of downstream target genes that encode pro-inflammatory cytokines and inducible enzymes, such as TNF-␣, IL-6, IL-1␤ and COX-2 [23, 24]. A number of studies reported showed that curcumin abrogates NF-B activation and reduces NF-B over-expression induced by LPS, TNF-␣ or H2O2
activities. We have also demonstrated that the water-soluble compound (A13) has dose-dependent anti-inflammatory activity and has the potential to be developed as a therapeutic agent. As an excellent leading compound, curcumin has been investigated in depth in the field of medicinal chemistry. A number of analogues of curcumin have also been designed and synthesized for the development of new anti-inflammatory and anti-cancer drugs
Curcumin can influence functions of different cells in a variety of ways [32] . Several structural moieties of curcumin, such as the ␤-diketone and phenolic hydroxyl group, have been reported to be responsible for the bioactivities of this compound [29] [30] [31] 33] . As previously reported, the reactive ␤-diketone was characterized as an important bioactivity-inducing moiety and may contribute to the anti-oxidant properties of curcumin [33, 34] . However, there The present acetone-derived B-class compounds are slightly more effective than cyclopentanone-derived A-class and cyclohexanone-derived C-class compounds, whereas our previous publication has suggested that the C-class compounds showed relatively higher activities than A-and B-class compounds according to the previous 43 compounds [18] . Taken all 87 analogues together, it is indicated that the structure of 5- reports [33, 35] Fig. 3, N,N [1, 2] . The inhibition of TNF-␣ and IL-6 release by A01, A03, A13, B18 and C22 in dose-dependent manner (Fig. 4 [9, 22-24, 36, 37] . As shown in Fig. 5 
) demonstrate their potential to be developed as anti-inflammatory agents. Besides TNF-␣ and IL-6, curcumin has been reported to exert its therapeutic effects via inhibiting various cytokines such as IL-1␤ and MCP-1, and key enzymes involved in the inflammatory response such as COX-2, PEGS and iNOS
